Drug Trial Radar · NCT00171171
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
Last checked: Nov 19, 2026Latest source record: Mar 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
252
Actual
Start
May 2004
Primary completion
Nov 2006
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a result of repeated blood transfusions. This study will evaluate the efficacy, safety and tolerability of deferasirox.
Conditions
- Beta-Thalassemia
- Hemosiderosis
Interventions
deferasiroxDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Liver Iron Concentration (as measured by biopsy)Time frame: at baseline and after 1 yeor of ICL670 treatment
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Cairo, Egypt
Ali Taher
Beirut, Lebanon
Novartis Investigative Site
Muscat, Oman
Novartis Investigative Site
Riyadh, Saudi Arabia
Novartis Investigative Site
Damascus, Syria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.